Xilio Therapeutics, Inc.
XLO
$0.7002
-$0.031-4.24%
| Weiss Ratings | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.61 | |||
| Price History | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -7.87% | |||
| 30-Day Total Return | -33.94% | |||
| 60-Day Total Return | -30.67% | |||
| 90-Day Total Return | -25.61% | |||
| Year to Date Total Return | -34.56% | |||
| 1-Year Total Return | -46.14% | |||
| 2-Year Total Return | -77.01% | |||
| 3-Year Total Return | -90.18% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -56.99% | |||
| 52-Week Low % Change | 16.06% | |||
| Price | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.70 | |||
| 52-Week Low Price | $0.63 | |||
| 52-Week Low Price (Date) | Feb 04, 2025 | |||
| 52-Week High Price (Date) | Feb 12, 2025 | |||
| Valuation | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 37.86M | |||
| Enterprise Value | -9.29M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.36 | |||
| Earnings Per Share Growth | -51.14% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.46 | |||
| Price/Book (Q) | 1.90 | |||
| Enterprise Value/Revenue (TTM) | -1.46 | |||
| Price | $0.70 | |||
| Enterprise Value/EBITDA (TTM) | 0.16 | |||
| Enterprise Value/EBIT | 0.16 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 64.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857-524-2466 | |||
| Address | 828 Winter Street Waltham, MA 02451 | |||
| Website | xiliotx.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -940.17% | |||
| Profit Margin | -918.04% | |||
| Management Effectiveness | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -56.48% | |||
| Return on Equity | -- | |||
| Income Statement | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 6.34M | |||
| Total Revenue (TTM) | 6.34M | |||
| Revenue Per Share | $0.10 | |||
| Gross Profit (TTM) | 6.34M | |||
| EBITDA (TTM) | -58.00M | |||
| EBIT (TTM) | -59.65M | |||
| Net Income (TTM) | -58.24M | |||
| Net Income Avl. to Common (TTM) | -58.24M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 25.84% | |||
| EPS Diluted (TTM) | -1.36 | |||
| EPS Diluted Growth (Q YOY) | 68.44% | |||
| Balance Sheet | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 55.29M | |||
| Cash Per Share (Q) | $0.85 | |||
| Total Current Assets (Q) | 60.23M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 17.60M | |||
| Current Ratio (Q) | 2.210 | |||
| Book Value Per Share (Q) | $0.38 | |||
| Total Assets (Q) | 71.08M | |||
| Total Current Liabilities (Q) | 27.26M | |||
| Total Debt (Q) | 8.14M | |||
| Total Liabilities (Q) | 53.48M | |||
| Total Common Equity (Q) | 17.60M | |||
| Cash Flow | XLO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -36.00K | |||
| Cash from Financing (TTM) | 29.20M | |||
| Net Change in Cash (TTM) | 10.78M | |||
| Levered Free Cash Flow (TTM) | -16.29M | |||
| Cash from Operations (TTM) | -18.38M | |||
